A 28-year-old woman with moderate-to-severe atopic dermatitis affecting >30% body surface area, unresponsive to optimized topical corticosteroids and emollients over 8 weeks, presents for systemic therapy. She has no contraindications to immunosuppression. What is the preferred first-line systemic agent according to current guidelines?

Explanation

## Systemic Therapy in Moderate-to-Severe Atopic Dermatitis **Key Point:** Dupilumab is now the preferred first-line biologic agent for moderate-to-severe AD unresponsive to topical therapy, with superior efficacy and safety profile compared to traditional systemic immunosuppressants. ### Evolution of Systemic AD Treatment Historically, cyclosporine was the gold standard. However, **2023 guidelines from AAD, EADV, and Indian Academy of Dermatology** now prioritize biologic agents, particularly dupilumab, due to: 1. **Superior efficacy** — EASI-75 (75% improvement in Eczema Area and Severity Index) achieved in 50–70% of patients at 16 weeks 2. **Favorable safety profile** — no bone marrow suppression, renal toxicity, or hypertension (unlike cyclosporine) 3. **Rapid onset** — clinical improvement within 2–4 weeks 4. **Sustained remission** — long-term control with maintenance dosing 5. **Mechanism** — blocks IL-4 receptor α, inhibiting both IL-4 and IL-13 signaling (core Th2 cytokines in AD pathogenesis) ### Comparison of Systemic Agents in AD | Agent | Onset | Efficacy | Safety Concerns | Current Role | |-------|-------|----------|-----------------|---------------| | **Dupilumab** | 2–4 weeks | EASI-75: 50–70% | Conjunctivitis, eosinophilia | **First-line biologic** | | **Cyclosporine** | 4–8 weeks | EASI-75: 40–50% | Nephrotoxicity, HTN, infections | Second-line if dupilumab unavailable | | **Methotrexate** | 8–12 weeks | EASI-75: 20–30% | Hepatotoxicity, cytopenias | Limited role; off-label | | **Azathioprine** | 12+ weeks | EASI-75: 10–20% | Hepatotoxicity, pancreatitis | Rarely used; poor efficacy | **High-Yield:** Dupilumab is approved for: - Moderate-to-severe atopic dermatitis (any age ≥6 months) - Concurrent moderate-to-severe asthma - Chronic rhinosinusitis with nasal polyps **Clinical Pearl:** Baseline and periodic monitoring for dupilumab includes: - Eosinophil count (mild elevation is expected; >1500/μL requires caution) - Conjunctivitis symptoms (most common adverse event; usually mild and manageable) - No routine renal or hepatic monitoring needed (unlike cyclosporine) **Mnemonic: "DUP-IL-4 = Dupilumab blocks IL-4 (and IL-13)"** — Remember: Dupilumab is the biologic of choice because it targets the Th2 axis at the receptor level.